Literature DB >> 23513792

[Curative treatment of hepatocellular carcinoma].

Hélène Barraud1, Jean-Pierre Bronowicki.   

Abstract

Hepatocellular carcinoma is the leading cause of death in cirrhotic patients and the third most common cause of cancer-related death. The main prognosis factors are related to tumor status (defined by number and sze of nodules, cell differentiation grade, vascular invasion, and extrahepatic spread), liver function (defined by Child-Pugh class, bilirubin, albumin, portal hypertension) and genera health status. Only a minority of patients (20-30%) are deemed suitable for potentially curative treatments including orthotopic liver transplantation and surgical resection. Only radiofrequency thermal ablation can challenge surgery for small size tumors but as after resection, local intrahepatic recurrences are common. Orthotopic liver transplantation offers hope for cure of both complicating cancer and the underlying chronic liver disease, cirrhosis, and for achieve the best outcomes in well-selected candidates. Hepatic resection is the treatment of choice in non-cirrhotic patients, where major resections can be performed with low rates of life-threatening complications and acceptable outcome.

Entities:  

Mesh:

Year:  2013        PMID: 23513792

Source DB:  PubMed          Journal:  Rev Prat        ISSN: 0035-2640


  4 in total

1.  Attenuated Listeria monocytogenes as a cancer vaccine vector for the delivery of CD24, a biomarker for hepatic cancer stem cells.

Authors:  Yu Yang; Jiajie Hou; Zhe Lin; Han Zhuo; Dianyu Chen; Xudong Zhang; Yun Chen; Beicheng Sun
Journal:  Cell Mol Immunol       Date:  2014-02-03       Impact factor: 11.530

2.  Treatment of human hepatocellular carcinoma by the oncolytic herpes simplex virus G47delta.

Authors:  Jiani Wang; Lihua Xu; Weigen Zeng; Pan Hu; Musheng Zeng; Samuel D Rabkin; Renbin Liu
Journal:  Cancer Cell Int       Date:  2014-09-19       Impact factor: 5.722

3.  Expression characteristics of KAI1 and vascular endothelial growth factor and their diagnostic value for hepatocellular carcinoma.

Authors:  Wu Zhang; Cheng Guang Zhao; Hong Yu Sun; Wei E Zheng; Hua Chen
Journal:  Gut Liver       Date:  2014-07-25       Impact factor: 4.519

4.  Oroxylin A activates PKM1/HNF4 alpha to induce hepatoma differentiation and block cancer progression.

Authors:  Libin Wei; Yuanyuan Dai; Yuxin Zhou; Zihao He; Jingyue Yao; Li Zhao; Qinglong Guo; Lin Yang
Journal:  Cell Death Dis       Date:  2017-07-20       Impact factor: 8.469

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.